The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association Stage B Heart Failure

Heart Failure Clinics

Volumn 8, Issue 2, 2012, Pages 247-253

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

ACC AHA; Heart failure; Left ventricular hypertrophy; Mineralocorticoid

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ADRENAL GLAND; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOXIA; MEDICAL SOCIETY; MORTALITY; OBESITY; REVIEW; SLEEP APNEA SYNDROME; UPREGULATION;

ADRENAL GLANDS; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ENALAPRIL; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYDROCORTISONE; HYPERTROPHY, LEFT VENTRICULAR; POTASSIUM; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 84858152650     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.11.001     Document Type: Review

References (48)

1. Guder G., Bauersachs J., Frantz S., et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754-1761.
2. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 1999, 341:709-717.
3. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
4. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
5. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558-565.
6. Pitt B., Bakris G., Ruilope L.M., et al. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 2008, 118:1643-1650.
7. Tomaschitz A., Pilz S., Ritz E., et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010, 31:1237-1247.
8. Beygui F., Vicaut E., Ecollan P., et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the albatross trial. Am Heart J 2010, 160:642-648.
9. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
10. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
11. Rossi G.P., Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039-1045.
12. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy study. Circulation 2003, 108:1831-1838.
13. Savoia C., Touyz R.M., Amiri F., et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.
14. Yoshida C., Goda A., Naito Y., et al. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertens 2011, 29:357-363.
15. Rocha R., Martin-Berger C.L., Yang P., et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
16. Duprez D., De Buyzere M., Rietzchel E., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998, 19:1371-1376.
17. Brilla C. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 2000, 47:1-3.
18. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES investigators. Circulation 2000, 102:2700-2706.
19. Martos R., Baugh J., Ledwidge M., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
20. Ramires F.J., Mansur A., Coelho O., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000, 85:1207-1211.
21. Shah N.C., Pringle S.D., Donnan P.T., et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007, 25:2345-2351.
22. Rocha R., Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002, 970:89-100.
23. Callera G.E., Touyz R.M., Tostes R.C., et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45:773-779.
24. Sam F., Xie Z., Ooi H., et al. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 2004, 17:188-193.
25. Usher M.G., Duan S.Z., Ivaschenko C.Y., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010, 120:3350-3364.
26. Ito K., Hirooka Y., Sunagawa K. Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. Circ Res 2009, 104:1004-1011.
27. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med 1992, 327:685-691.
28. Funder J.W. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93:121-125.
29. Bocchi B., Kenouch S., Lamarre-Cliche M., et al. Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension 2004, 43:803-808.
30. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453-459.
31. Goette A., Hoffmanns P., Enayati W., et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001, 88:906-909. A908.
32. Mosso L.M., Carvajal C.A., Maiz A., et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007, 25:2125-2130.
33. Stiefel P., Vallejo-Vaz A., Morillo S., et al. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011, 2011. Article ID 685238, 8 pages. 10.4061/2011/685238.
34. Shibata S., Fujita T. The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep 2011, 13:109-115.
35. Pitt B. Plasma aldosterone levels in patients with coronary artery disease (CAD) without heart failure or myocardial infarction: implications for pathophsiology, prognosis, and therapy. Eur Heart J 2011, [Epub ahead of print].
36. Leopold J.A., Dam A., Maron B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189-197.
37. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216.
38. Keidar S., Kaplan M., Pavlotzky E., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
39. Takai S., Jin D., Muramatsu M., et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135-1139.
40. Ezeckowitz J., McAllister F. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009, 30(4):469-477.
41. Okubo S., Niimura F., Nishimura H., et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997, 99:855-860.
42. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004, 6:539-545.
43. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
44. Min L.J., Mogi M., Li J.M., et al. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005, 97:434-442.
45. Hori Y., Yoshioka K., Kanai K., et al. Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats. Biol Pharm Bull 2011, 34:61-65.
46. Davies J.I., Band M., Morris A., et al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004, 47:1687-1694.
47. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
48. 1(c) levels in patients with chronic heart failure. Am Heart J 2010, 160:915-921.